To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Key Inclusion Criteria: Have a primary diagnosis of schizophrenia History of at least 1 prior episode of acute schizophrenia in the 3 years preceding screening History of schizophrenia requiring continuous antipsychotic treatment for at least 1 years preceding screening Clinically stable at the time of entry defined by at least a 4 week period of stable symptoms Key Exclusion Criteria: Have an uncontrolled, unstable clinically significant medical condition History of suicide attempt or significant violence to others in the past 2 years A substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse Current substance abuse/dependence Concurrent psychiatric disorder other than schizophrenia.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
asenapine
placebo